PARNF — Parnell Pharmaceuticals Holdings Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $1.44m
- $11.71m
- AU$13.17m
Brief: Parnell Pharmaceuticals sees FY 2016 revenue of $14 million to $16 million
Brief: Parnell Pharmaceuticals says manufacturing deal with Merial
Brief: Parnell Pharmaceuticals announces pricing of underwritten public offering
Brief: Parnell Pharmaceuticals Q1 revenue rose 43 percent to $2.2 mln
Brief: Parnell Pharmaceuticals to offer shares with aggregate offering price $5 mln
U.S. RESEARCH ROUNDUP-Applied Materials, Tegna, Nasdaq
Brief: Parnell Pharmaceuticals says expects to continue to receive patent grants relating to Zydax in 2016
Brief: Parnell files for sale of up to 2.1 mln shares by selling stockholder
Brief: Parnell Pharmaceuticals announces agreement with Lincoln park captial fund to purchase ordinary shares
Brief: Parnell appoints Ellen Richstone, David Rosen to Board
Brief: Parnell Pharma says Q3 loss per share A$0.18
Brief: Parnell Pharmaceuticals restructures board
Brief: Parnell Pharmaceuticals announces financial results for the six-month period ended June 30
Brief: Parnell Pharmaceuticals says $11 mln secured term loan facility
Brief: Parnell Pharmaceuticals announces positive top-line pivotal trial results for Zydax(R), disease-modifying osteoarthritis drug in dogs
Brief: Parnell Pharmaceuticals Q1 EPS $0.004
Brief: Parnell Pharma board approves a fiscal year-end change from June 30 to Dec 31
Dogs, hogs and dairy cows: 'Animal pharm' catches Wall Street's attention